Tech Company Financing Transactions
Karuna Therapeutics Funding Round
Karuna Therapeutics closed a $68 million Series B funding round on 3/19/2019. Investors included Arch Venture Partners, Alexandria Venture Investments and Eventide Asset Management.
Transaction Overview
Company Name
Announced On
3/19/2019
Transaction Type
Venture Equity
Amount
$68,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the development of KarXT into several new indications, including geriatric psychosis and pain, progress new formulations of KarXT, expand the pipeline, and continue to build company infrastructure.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
33 Arch St. 3110
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Overview
Karuna Therapeutics (Nasdaq: KRTX) is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Paul
Chief Financial Officer
Troy Ignelzi
Chief Medical Officer
Stephen Brannan
Chief Operating Officer
Andrew Miller
Vice President
Giorgio Attardo
VP - Finance
Jason Brown
VP - R & D
Christian Felder
Browse more venture capital transactions:
Prev: 3/16/2019: Zeus venture capital transaction
Next: 3/19/2019: Tibber venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs